Table of Content

1. Product Overview
2. Research Methodology
3. Executive Summary
4. Impact of COVID-19 on Global Radioligand Therapy Market
5. Voice of Customer
6. Clinical Trial Analysis
7. Global Radioligand Therapy Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Indication (Prostate Cancer, Neuroendocrine Tumor, Others)
7.2.2. By Product (Lutathera, Zytiga, Xtandi, Xofigo)
7.2.3. By Biomarker (Prostate-Specific Membrane Antigen, Ki 67 Expression and Grading, Cytochrome P450 17A1 Inhibitor)
7.2.4. By End User (Biotechnology & Pharmaceutical Companies, Academic & Research Institutions, Others)
7.2.5. By Region
7.2.6. By Company (2021)
7.3. Market Map
8. North America Radioligand Therapy Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Indication
8.2.2. By Product
8.2.3. By Biomarker
8.2.4. By End User
8.2.5. By Country
8.3. North America: Country Analysis
8.3.1. United States Radioligand Therapy Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Indication
8.3.1.2.2. By Product
8.3.1.2.3. By Biomarker
8.3.1.2.4. By End User
8.3.2. Canada Radioligand Therapy Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Indication
8.3.2.2.2. By Product
8.3.2.2.3. By Biomarker
8.3.2.2.4. By End User
8.3.3. Mexico Radioligand Therapy Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Indication
8.3.3.2.2. By Product
8.3.3.2.3. By Biomarker
8.3.3.2.4. By End User
9. Europe Radioligand Therapy Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Indication
9.2.2. By Product
9.2.3. By Biomarker
9.2.4. By End User
9.2.5. By Country
9.3. Europe: Country Analysis
9.3.1. France Radioligand Therapy Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Indication
9.3.1.2.2. By Product
9.3.1.2.3. By Biomarker
9.3.1.2.4. By End User
9.3.2. Germany Radioligand Therapy Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Indication
9.3.2.2.2. By Product
9.3.2.2.3. By Biomarker
9.3.2.2.4. By End User
9.3.3. United Kingdom Radioligand Therapy Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Indication
9.3.3.2.2. By Product
9.3.3.2.3. By Biomarker
9.3.3.2.4. By End User
9.3.4. Italy Radioligand Therapy Market Outlook
9.3.4.1. Market Size & Forecast
9.3.4.1.1. By Value
9.3.4.2. Market Share & Forecast
9.3.4.2.1. By Indication
9.3.4.2.2. By Product
9.3.4.2.3. By Biomarker
9.3.4.2.4. By End User
9.3.5. Spain Radioligand Therapy Market Outlook
9.3.5.1. Market Size & Forecast
9.3.5.1.1. By Value
9.3.5.2. Market Share & Forecast
9.3.5.2.1. By Indication
9.3.5.2.2. By Product
9.3.5.2.3. By Biomarker
9.3.5.2.4. By End User
10. Asia-Pacific Radioligand Therapy Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Indication
10.2.2. By Product
10.2.3. By Biomarker
10.2.4. By End User
10.2.5. By Country
10.3. Asia-Pacific: Country Analysis
10.3.1. China Radioligand Therapy Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Indication
10.3.1.2.2. By Product
10.3.1.2.3. By Biomarker
10.3.1.2.4. By End User
10.3.2. India Radioligand Therapy Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Indication
10.3.2.2.2. By Product
10.3.2.2.3. By Biomarker
10.3.2.2.4. By End User
10.3.3. Japan Radioligand Therapy Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Indication
10.3.3.2.2. By Product
10.3.3.2.3. By Biomarker
10.3.3.2.4. By End User
10.3.4. South Korea Radioligand Therapy Market Outlook
10.3.4.1. Market Size & Forecast
10.3.4.1.1. By Value
10.3.4.2. Market Share & Forecast
10.3.4.2.1. By Indication
10.3.4.2.2. By Product
10.3.4.2.3. By Biomarker
10.3.4.2.4. By End User
10.3.5. Australia Radioligand Therapy Market Outlook
10.3.5.1. Market Size & Forecast
10.3.5.1.1. By Value
10.3.5.2. Market Share & Forecast
10.3.5.2.1. By Indication
10.3.5.2.2. By Product
10.3.5.2.3. By Biomarker
10.3.5.2.4. By End User
11. South America Radioligand Therapy Market Outlook
11.1. Market Size & Forecast
11.1.1. By Value
11.2. Market Share & Forecast
11.2.1. By Indication
11.2.2. By Product
11.2.3. By Biomarker
11.2.4. By End User
11.2.5. By Country
11.3. South America: Country Analysis
11.3.1. Brazil Radioligand Therapy Market Outlook
11.3.1.1. Market Size & Forecast
11.3.1.1.1. By Value
11.3.1.2. Market Share & Forecast
11.3.1.2.1. By Indication
11.3.1.2.2. By Product
11.3.1.2.3. By Biomarker
11.3.1.2.4. By End User
11.3.2. Argentina Radioligand Therapy Market Outlook
11.3.2.1. Market Size & Forecast
11.3.2.1.1. By Value
11.3.2.2. Market Share & Forecast
11.3.2.2.1. By Indication
11.3.2.2.2. By Product
11.3.2.2.3. By Biomarker
11.3.2.2.4. By End User
11.3.3. Colombia Radioligand Therapy Market Outlook
11.3.3.1. Market Size & Forecast
11.3.3.1.1. By Value
11.3.3.2. Market Share & Forecast
11.3.3.2.1. By Indication
11.3.3.2.2. By Product
11.3.3.2.3. By Biomarker
11.3.3.2.4. By End User
12. Middle East and Africa Radioligand Therapy Market Outlook
12.1. Market Size & Forecast
12.1.1. By Value
12.2. Market Share & Forecast
12.2.1. By Indication
12.2.2. By Product
12.2.3. By Biomarker
12.2.4. By End User
12.2.5. By Country
12.3. MEA: Country Analysis
12.3.1. South Africa Radioligand Therapy Market Outlook
12.3.1.1. Market Size & Forecast
12.3.1.1.1. By Value
12.3.1.2. Market Share & Forecast
12.3.1.2.1. By Indication
12.3.1.2.2. By Product
12.3.1.2.3. By Biomarker
12.3.1.2.4. By End User
12.3.2. Saudi Arabia Radioligand Therapy Market Outlook
12.3.2.1. Market Size & Forecast
12.3.2.1.1. By Value
12.3.2.2. Market Share & Forecast
12.3.2.2.1. By Indication
12.3.2.2.2. By Product
12.3.2.2.3. By Biomarker
12.3.2.2.4. By End User
12.3.3. UAE Radioligand Therapy Market Outlook
12.3.3.1. Market Size & Forecast
12.3.3.1.1. By Value
12.3.3.2. Market Share & Forecast
12.3.3.2.1. By Indication
12.3.3.2.2. By Product
12.3.3.2.3. By Biomarker
12.3.3.2.4. By End User
13. Market Dynamics
13.1. Drivers
13.2. Challenges
14. Market Trends & Developments
15. Competitive Landscape (Inclusive SWOT Analysis)
15.1. Novartis International, AG
15.2. Johnson & Johnson
15.3. Pfizer, Inc.
15.4. Amneal Pharmaceuticals LLC.
15.5. POINT Biopharma Global Inc
15.6. Fusion Pharmaceuticals Inc.
15.7. Clovis Oncology, Inc.
15.8. Telix Pharmaceuticals Limited
15.9. Lantheus Holdings, Inc.
15.10. Progenics Pharmaceuticals
15.11. Bayer AG
16. Strategic Recommendations